Optimal treatment

ApprovedSmall molecule

UUniversity of California, San Francisco

Optimal treatment is one of 64 small molecule programs targeting Stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Heart FailureActive, not recruiting

StrokeApproved

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Optimal treatment

UUniversity of California, San Francisco

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Amidate

Pfizer

Preclinical

1 4

LCZ696

Novartis

Preclinical

15 5

Activase

Savaysa

Xylocaine

1 8

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 10

Adriamycin

GGynecologic Oncology Group

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Recruiting

Heart Failure

NCT06516562

Clinical

Trials by Indication[1]

Stroke1 trial

Quality Improvement in Stroke Prevention (QUISP)

Completed·UUniversity of California, San Francisco·Phase 4·NCT00328640·1,500 enrolled

Heart Failure1 trial

Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study

Recruiting·UUniversity Medical Center Ho Chi Minh City (UMC)··NCT06516562·2,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Optimal treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Optimal treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Optimal treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, San Francisco

Optimal treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Stroke1 trial

Heart Failure1 trial

References

Drug Info

Quick Facts

Related News